A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma

• Published in: Gynecologic oncology 2013-02, Vol.128 (2), p.215-220
• Main Authors: Campos, Susana M, Penson, Richard T, Matulonis, Ursula, Horowitz, Neil S, Whalen, Christin, Pereira, Lauren, Tyburski, Karin, Roche, Maria, Szymonifka, Jackie, Berlin, Suzanne
• Format: Article
• Language: English
• Subjects: Adult; Aged; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Angiogenic biomarkers; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms - drug therapy; Female; Hematology, Oncology and Palliative Medicine; Humans; Indoles - administration & dosage; Indoles - adverse effects; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Obstetrics and Gynecology; Ovarian cancer; Ovarian Neoplasms - blood supply; Ovarian Neoplasms - drug therapy; Peritoneal Neoplasms - drug therapy; Protein Kinase Inhibitors - administration & dosage; Pyrroles - administration & dosage; Pyrroles - adverse effects; Targeted therapy; Tyrosine kinase inhibitors
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2012.07.126

Abstract Objective Ovarian cancer is a highly angiogenic tumor and a model for antiangiogenic research. The tyrosine kinase receptor inhibitors target several receptors allowing for the pharmacological disruption of several independent pathways. Sunitinib malate® is a multitargeted tyrosine kinase inhibitor. A phase II study utilizing a modified dosing schedule was conducted to assess the efficacy and safety of Sunitinib® in recurrent ovarian, fallopian tube and peritoneal carcinoma. Methods A nonrandomized phase II study was modeled as a two-stage Simon design initially enrolling 17 evaluable participants in stage one and 18 patients in stage two. Patients received the study drug at 37.5 mg every day over a 28 day treatment cycle until clinical or radiological evidence of progressive disease. Disease was evaluated radiographically and best overall response was defined using the RECIST 1.0 criteria. The primary objective of this study was to define the response rate (defined as complete response and partial response) while the secondary objectives included both the progression free rate as well as the safety of this agent in this patient population. Results The response rate (PR + CR) was 8.3% (95% confidence interval: 1.8%, 22.5%). The 16-week and 24 week progression-free survival estimate was 36% (95% confidence interval and 19.2%), respectively. The median progression-free survival estimate was 9.9 weeks. Hypertension and gastrointestional events were the most common toxicities noted. Conclusions A modest response rate of 8.3% was achieved with Sunitinib malate®. This phase II study adds to the body of literature of VEGFR inhibitors and further underscores the need of defining a genetic angiogenic signature.